

Bibliography:

- Aminoff, M.J. 2009. Pharmacologic Management of Parkinsonism & Other Movement Disorders. (In Katzung, B.G., Masters, S.B. & Trevor, A.J. Basic and Clinical Pharmacology. 11th ed. McGraw-Hill Lange: New York. 469-486).
- Auluck, P.K., Chan, H.Y., Trojanowski, H.Q., Lee, V.M. & Bonini, N.M. 2002. Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson's disease. *Science*. 295:865-868.
- Bekris, L.M., Mata, I.F. & Zabetian, C.P. 2010. The genetics of Parkinson's disease. *Journal of Geriatric Psychiatry and Neurology*. 23:228-242.
- Belmaker, R.H. & Agam, G. 2008. Major depressive disorder. *New England Journal of Medicine*. 358:55-65.
- Binda, C., Li, M., Hubalék, F., Restelli, N., Edmondson, D.E. & Mattevi, A. 2003. Insights into the mode of inhibition of human mitochondrial monoamine oxidase B from high-resolution crystal structures. *Proceedings of the National Academy of Sciences of the United States of America*. 100:9750-9755.
- Binda, C., Wang, J., Pisani, L., Caccia, C., Caroti, A., Salvati, P., Edmondson, D. & Mattevi, A. 2007. Structures of human monoamine oxidase B with selective non-covalent inhibitors: safinamide and coumarin analogues. *Journal of Medicinal Chemistry*. 50:5848-5852.
- Blaschko, H. & Duthie, R. 1945. The inhibition of amine oxidase by amidines. *Biochemistry*. 39:347-350.
- Bonifati, V. & Meco, G. 1999. New, selective catechol-O-methyltransferase inhibitors as selected therapeutic agents in Parkinson's disease. *Pharmacology & Therapeutics*. 81:1-36.
- Coryell, W. 2011. Mood Disorders. (In Porter, R.S. & Kaplan, J.L. The Merck Manual of Diagnosis and Therapy. 19th ed. Merck Sharpe & Dohme corp: New Jersey. 1538-1547).
- Cubría, J.C., Ordóñez, D., Álvarez-Bujidos, M.L., Negro, A. & Ortiz, A.I. 1991. Inhibition of diamine oxidase from porcine kidney by pentamidine and other aminoguanidine compounds. *Comparative Biochemistry and Physiology*. 100B:543-546.
- Da Prada, M., Zürcher, G., Wüthrich, I. & Haefely, W.E. 1988. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. *Journal of Neural Transmission*. 26(suppl.): 31-56.
- Dauer, W. & Przedborski, S. 2003. Parkinson's disease: mechanisms and models. *Neuron*. 39:889-909.
- Davison, A.N. 1958. The irreversible inhibition of monoamine oxidase *in vivo*. *Archives of Biochemistry and Biophysics*. 77:368-371.
- Di Giovanni, S., Eleuteri, S., Paleologou, K.E., Yin, G., Zweckstetter, M., Carrupt, P.A. & Lashuel, H.A. 2010. Entacapone and tolcapone, two catechol O-methyltransferase inhibitors, block fibril formation of α -synuclein and β -amyloid and protect against amyloid-induced toxicity. *Journal of Biological Chemistry*. 285:14941-14954.

- Edmondson, D.E., Mattevi, A., Binda, C., Li, M. & Hubálek, F. 2004. Structure and mechanism of monoamine oxidase. *Current Medicinal Chemistry*. 11:1983-1993.
- Edmondson, D.E., Binda, C. & Mattevi, A. 2007. Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B. *Archives of Biochemistry and Biophysics*. 464:269-276.
- Edmondson, D. E., Binda, C., Wang, J., Upadhyay, A.K. & Mattevi, A. 2009. Molecular and mechanistic properties of the membrane-bound mitochondrial monoamine oxidases. *Biochemistry*. 48:4220-4230.
- Eidelberg, D. & Pourfar, M. 2011. Movement and Cerebellar Disorders. (In Porter, R.S. & Kaplan, J.L. The Merck Manual of Diagnosis and Therapy. 19th ed. Merck Sharpe & Dohme corp: New Jersey. 1765-1770).
- Fearnley, J.M. & Lees, A.J. 1991. Ageing and Parkinson's disease substantia nigra regional selectivity. *Brain*. 114:2283-2301.
- Ferrer, I. 2011. Neuropathology and neurochemistry of nonmotor symptoms in Parkinson's disease. *Parkinson's Disease*. 2011:1-13.
- Garrett, R.H. & Grisham, C. 2002. Principles of Biochemistry with a Human Focus. Harcourt College Publishers: Fort Worth. 320-345.
- Gerlach, M., Reichmann, H. & Riederer, P. 2012. A critical review of evidence for preclinical differences between rasagiline and selegiline. *Basal ganglia*. 2(suppl.):S9-S15.
- Gill, S.S., Patel, N.K., Hotton, G.R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D.J., Svendsen, C.N. & Heywood, P. 2003. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. *Nature Medicine*. 9:589-595.
- Goole, J. & Amighi, K. 2009. Levodopa delivery systems for the treatment of Parkinson's disease: an overview. *International Journal of Pharmaceutics*. 380:1-15.
- Harfenist, M., Heuser, D.J., Joyner, C.T., Batchelor, J.F. & White, H.L. 1996. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups. *Journal of Medicinal Chemistry*. 39:1857-1863.
- Hernán, M.A., Takkouche, B., Caamaño-Isorna, F. & Gestal-Otero, J.J. 2002. A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. *Annals of Neurology*. 52:276-284.
- Huang, R., Southall, N., Wang, Y., Yasgar, A., Shinn, P., Jadhav, A., Nguyen, D.C. & Austin, C.P. 2012. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. *Science Translational Medicine*. 3:80-96.
- Hubálek, F., Binda, C., Khalil, A., Li, M., Mattevi, A., Castagnoli, N. & Edmondson, D.E. 2005. Demonstration of isoleucine 199 as a structural determinant for the selective inhibition of human monoamine oxidase B by specific reversible inhibitors. *Journal of Biological Chemistry*. 280:15761-15766.

- Kirchmair, J., Markt, P., Distinto, S., Wolber, G. & Langer, T. 2008. Evaluation of the performance of 3D virtual screening protocols: RMSD comparisons, enrichment assessments and decoy selection: what can we learn from earlier mistakes? *Journal of Computer Aided Molecular Design*. 22:213-218.
- Lang, A.E. & Lozano, A.M. 1998. Medical Progress: Parkinson's disease. *The New England Journal of Medicine*. 339:1044-1053.
- Langer, T. & Wolber, G. 2004. Pharmacophore definition and 3D searches. *Drug Discovery Today: Technologies*. 1:203-207.
- Langston, J.W. & Ballard, P. 1984. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): implications for treatment and the pathogenesis of Parkinson's disease. *Canadian Journal of Neurological Sciences*. 11(suppl.):160-165.
- Lee, J.L., Baek, S. & Kim, Y. 2007. Receptor-oriented pharmacophore-based *in silico* screening of human catechol-O-methyltransferase for the design of anti-parkinsonian drug. *Bulletins of the Korean Chemical Society*. 28:379-385.
- Lee, S.J. 2008. Origins and effects of extracellular α -synuclein: implications in Parkinson's disease. *Journal of Molecular Neuroscience*. 34:17-22.
- Legoabe, L., Kruger, J., Petzer, A. L., Bergh, J. J. & Petzer, J. P. 2011. Monoamine oxidase inhibition by selected anilide derivatives. *European Journal of Medicinal Chemistry*. 46:5162-5174.
- Lipski, J., Nistico, R., Berretta, N., Guatteo, E., Bernardi, G. & Mercuri, N.B. 2011. L-DOPA: a scapegoat for accelerated neurodegeneration in Parkinson's disease? *Progress in Neurobiology*. 94:389-407.
- Magyar, K. & Szende, B. 2004. (R)-Deprenyl, a selective MAO-B inhibitor, with apoptotic and anti-apoptotic properties. *Neurotoxicology*. 25:233-242.
- Manley-King, C.I., Bergh, J.J. & Petzer, J.P. 2011. Inhibition of monoamine oxidase by selected C5- and C6-substituted isatin analogues. *Bioorganic & Medicinal Chemistry*. 19:261-274.
- Männistö, P.T. & Kaakkola, S. 1990. Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology and clinical efficacy of the new selective COMT inhibitors. *Pharmacological Reviews*. 51:593-628.
- Medina-Franco, J., Giulianotti, M.A., Welmaker, G.S. & Houghten, R.A. 2013. Shifting from the single to multidrug paradigm in drug discovery. *Drug Discovery Today*. 18:9-10.
- Meyer, J.L., Ginovart, N., Boovariwala, A., Sagrati, S., Hussey, D., Garcia, A., Young, T., Praschak-Rieder, N., Wilson, A.A. & Houle, S. 2006. Elevated monoamine oxidase A levels in the brain: an explanation for the monoamine imbalance of major depression. *Archives of General Psychiatry*. 63:1209-1216.
- Muchowski, P.J. 2002. Protein misfolding, amyloid formation, and neurodegeneration: a critical role for molecular chaperones. *Neuron*. 35:9-12.

- Mukherjee, J. & Yang, Z.H. 1999. Monoamine oxidase A inhibition by fluoxetine: an *in vitro* and *in vivo* study. *Synapse*. 31:285-289.
- Nagatsu, T. 2004. Progress in monoamine oxidase (MAO) research in relation to genetic engineering. *Neurotoxicology*. 25:11-20.
- Oates, N.S., Shah, R.R., Idle, J.R. & Smith, R.L. 1983. Influence of oxidation polymorphism on phenformin kinetics and dynamics. *Clinical Pharmacology & Therapeutics*. 34:827-834.
- Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N. & Olanow, C.W. 2000. Pathophysiology of the basal ganglia in Parkinson's disease. *Trends in Neurosciences*. 23(suppl.):S8-S19.
- Okada, M., Nakao, R., Hosoi, R. & Zhang, M.R. 2011. Microdialysis with radiometric monitoring of *L*-[β -¹¹C]DOPA to assess dopaminergic metabolism: effect of inhibitors of *L*-amino acid decarboxylase, monoamine oxidase, and catechol-*O*-methyltransferase on rat striatal dialysate. *Journal of Cerebral Blood Flow and Metabolism*. 31:124-131.
- Orr, C.F., Rowe, D.B., Mizuno, Y., Mori, H. & Halliday, G.M. 2005. A possible role for humoral immunity in the pathogenesis of Parkinson's disease. *Brain*. 128:2665-2674.
- Pae, C.U., Bodkin, J.A., Portland, K.B., Thase, M.E. & Patkar, A.A. 2012. Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. *Journal of Clinical Psychiatry*. 73:661-668.
- Petzer, A., Harvey, B.H., Wegener, G. & Petzer, J.P. 2012. Azure B, a metabolite of methylene blue, is a high-potency, reversible inhibitor of monoamine oxidase. *Toxicology and Applied Pharmacology*. 258:403-409.
- Petzer, A., Pienaar, A. & Petzer, J.P. 2013. The inhibition of monoamine oxidase by esomeprazole. *Arzneimittelforschung*. 63:462-467.
- Ramsay, R.R., Dunford, C. & Gillman P.K. 2007. Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. *British Journal of Pharmacology*. 152:946-951.
- Ramsay, R.R. 2012. Monoamine oxidases: The biochemistry of the proteins as targets in medicinal chemistry and drug discovery. *Current Topics in Medicinal Chemistry*. 12:2189-2209.
- Ross, C.A. & Poirier, M.A. 2004. Protein aggregation and neurodegenerative disease. *Nature Medicine*. 10(suppl.):S10-S17.
- Seidel, T., Ibis, G., Bendix, F. & Wolber, G. 2010. Strategies for 3D pharmacophore based virtual screening. *Drug Discovery Today: Technologies*. 7:221-228.
- Silverman, R.B. 2004. *The Organic Chemistry of Drug Design and Drug Action*. 2nd ed. Elsevier Academic Press: Illinois. 241-303.
- Son, S., Ma, J., Kondou, Y., Yoshimura, M., Yamashita, E. & Tshukihara, T. 2008. Structure of human monoamine oxidase A at 2.2-Å resolution: the control of opening the entry for

substrates/inhibitors. *Proceedings of the National Academy of Sciences of the United States of America*. 105:5739-5744.

Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. & Goedert, M. 1997. Alpha-synuclein in Lewy bodies. *Nature*. 388:839-840.

Strydom, B., Malan, S.F., Castagnoli, N., Bergh, J.J. & Petzer, J.P. 2010. Inhibition of monoamine oxidase B by 8-benzoyloxycaffeine analogues. *Bioorganic & Medicinal Chemistry*. 18:1018-1028.

Weinreb, O., Amit, T., Bar-Am, O. & Youdim, M.B.H. 2010. Rasagiline: A novel anti-parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity. *Progress in Neurobiology*. 92:330-344.

Wisplewey, B. & Pearson, R.D. 1991. Pentamidine: a review. *Infection Control and Hospital Epidemiology*. 12:375-382.

Xian, M., Li, X., Tang, X., Chen, X., Zheng, Z., Galligan, J.J., Kreulen, D.L. & Wang, P.G. 2001. N-hydroxyl derivatives of guanidine based drugs as enzymatic NO donors. *Bioorganic & Medicinal Chemistry Letters*. 11:2377-2380.

Yamada, M. & Yasuhara, H. 2004. Clinical pharmacology of MAO inhibitors: safety and future. *Neurotoxicology*. 25:215-221.


Youdim, M.B.H. & Bakhle, Y.S. 2006. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. *British Journal of Pharmacology*. 147(suppl.):S287-S296.

Zecca, L., Youdim, M.B.H., Riederer, P., Connor, J.R. & Crichton, R.R. 2004. Iron, brain ageing and neurodegenerative disorders. *Nature Reviews Neuroscience*. 5:863-873.

Acknowledgements:

- My Heavenly Father for giving me the talents and opportunities to make this study possible.
- My supervisor, Prof. J.P. Petzer for all his patience, planning, assistance and support with this study.
- My co-supervisor, Dr. A. Petzer for all her assistance with the enzymology.
- My parents- Kallie and Annemarie- and family – Fanie, Finney and Esté- for believing in me and all their support.
- All my friends for their encouragement and support.
- The North-West University for providing the facilities and financial support that made this study possible.
- This work is based on the research supported in part by the Medical Research Council and National Research Foundation of South Africa [Grant specific reference numbers (UID) 85642 and 80647]. The Grantholders acknowledge that opinions, findings and conclusions or recommendations expressed in any publication generated by the NRF supported research are that of the authors and that the NRF accepts no liability whatsoever in this regard.

Annexure A – Letter of permission



Ms. M. Barkhuizen

1 November 2013

To whom it may concern:

Dear Sir / Madam

CO-AUTHORSHIP ON RESEARCH PAPERS

The undersigned, as co-authors of the research article listed below, hereby give permission to Ms. Melinda Barkhuizen to submit the paper as part of the degree M.Sc. in Pharmaceutical Chemistry at the North-West University, Potchefstroom Campus.

I. The inhibition of monoamine oxidase by phenformin and pentamidine.

Yours sincerely,

Prof. J.P. Petzer

Dr. A. Petzer

Annexure B – Author instructions and letter of permission to use article.

Arzneimittelforschung/ Drug Research

Information for Authors

Arzneimittelforschung/Drug Research accepts manuscripts in English covering drug research and development as well as the latest scientific findings on substances and/or products already marketed. The journal accepts manuscripts from the following areas: analytics, bioavailability, biochemistry, bioequivalence, chemistry, clinical pharmacology, drug interactions, efficacy testing, experimental pharmacology, pharmacodynamics, pharmacokinetics, teratology, toxicology as well as questions relating to drug formulation, mathematical and statistical methods for the evaluation of results from industrial investigations as well as clinical trials. Translational medicine aspects are key features of the journal.

When submitted, manuscripts must not have been published elsewhere or be under simultaneous consideration by another journal. The aim of the journal is to disseminate new and reliable experimental data from across the field of drug research to researchers, scientists and doctors worldwide.

N.B.: Incorrect English can result in the immediate rejection of your manuscript whereas correct English will help a speedy publication process. It is in your own interest to ensure that your paper has been read by a native speaker of English; alternatively, you should use a copy-editing service like "American Journal Experts" if you have concerns about the English in your manuscript.

These types of manuscripts will be accepted:

- Original Articles
- Reviews
- Commentaries
- Controversies
- Opinion Papers
- Short Communications
- Letters

Clinical Trials

The Journal supports trial registration. All trials reported must be registered at an official registry recognised by the International Committee of Medical Journal Editors, such as ClinicalTrials.gov (www.clinicaltrials.gov) or any of the primary registries on the World Health Organization's International Clinical Trial Registry Platform (www.who.int/ictrp).

Conflict of Interest

Please state the conflicts of interest of all authors.

During the online submission process, you will be asked to declare your conflicts of interest. Failure to do so or an incomplete declaration may result in non-publication.

Ethics

The journal is very concerned about ethical standards. Please provide proof that the terms of the latest version of the "World Medical Association Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects" have been adhered to or provide approval of your local ethics committee. The same applies to animals. Please provide proof that experiments involving animals were carried out in compliance with the "Guide for the Care and Use of Laboratory animals" published by the National Academy of Sciences or else provide approval of your local ethics committee.

Manuscript Submission

All manuscripts must be submitted exclusively via online submission at <http://mc.manuscriptcentral.com/amf>

Submissions of hardcopy manuscripts will not be accepted. Please include tables and figures as separate files, they should not be integrated into the main document, but a list with the legends of the figures and tables should be included there. Provide graphic files with sufficient resolution: coloured and black-white bitmaps: 300 dpi; diagrams and line drawings: 600 dpi minimum. Figures

should be serially numbered with Arabic numerals. There should be a clear mark in the manuscript indicating where the figure should be inserted.

Authors are responsible for the correctness of the manuscripts and the list of references. All measurements must be in Systeme International (SI) units.

A. Original Articles

Original papers should deal with investigations and results of high scientific value which have not been published previously.

1. Original papers should not exceed 6 printed pages, i.e. 15 type-written double-spaced manuscript pages of 30 lines of 60 letters each, including references, tables, figures and legends. Please do not use more than one blank space between words and sentences.

2. Preparation of manuscripts

Authors are asked to follow the outline set below:

Page 1: a) title, b) short running title (limit: 40 characters), c) name of the author (no titles or academic grades) and address of the institute(s) where the investigations have been carried out. Should the address of the author at the time of publication differ from the one stated in the paper, the current address should be stated in a footnote, d) complete mailing address of corresponding author including telephone and telefax numbers and e-mail addresses.

Page 2: a) a structured abstract containing no more than 250 words with no abbreviations, b) keywords (3–6 without repeating words in the title).

Page 3 and onwards: a) introduction also indicating the aim of the study, b) materials and methods, c) results: double presentation of data in the form of text, tables or figures should be avoided, d) discussion and conclusions, e) list of references, f) legends of tables and figures. Do include your acknowledgements in the main document.

3. References

a) *Text:* Citations and references should be numbered consecutively using square brackets in the order in which they are cited in the text, followed by any in tables or legends. Please do not number references under alphabetical order of authors. Do not use footnotes and hyperlinks. If authors are mentioned in the text, only the first author should be given followed by "et al." whenever the reference has three or more authors. Example: "...protein concentrations were determined according to Lowry et al. [1]."

b) *List of References:* References should be given as plain text. Do not use fields in MS Word, as these are difficult to process later. The references should be listed in numbered order according to the sequence they appear in the text. Preferably, all authors or groups of authors of each publication should be mentioned. The name of the author(s) should be followed by the full title of the paper, name of the journal in which it has been published (abbreviations according to "Index Medicus"), year of publication, volume, first and last page. Abstracts and supplements have to be indicated. Chapters from books have to be cited as follows: author(s), title of chapter, title of book, editor(s), place of publication, publisher, year of publication, first and last page of the chapter. See also the recommendations of the International Committee of Medical Journal Editors (www.icmje.org). Examples:

1 Park HY, Lim H, Pyo H, Kwon YS. Downregulation of matrix metalloproteinase-13 by the root extract of *Caythula officinalis* Kuan and its constituents in IL-1 β -treated chondrocytes. *Planta Med* 2011; 75: 1528–1530

2 Kerner W, Pfeiffer EF. The artificial pancreas. In: Samols E (ed). *The endocrine pancreas*. New York: Raven Press, 1991: 441–456

B. Reviews

Reviews deal with previous research on a certain topic and serve to summarize current findings on the topic so far. The structure of the review will vary from an original paper according to the nature of the review, but please adhere to the guidelines concerning refer-

ences. Please aim at no more than 20 type-written pages and 100 references.

C. Commentaries

They usually follow the article that they discuss, have no special structure and are usually invited. They could also deal with an actual topic such as pivotal new scientific findings in the field. Commentaries should not exceed 6 type-written pages, with a maximum of 20 references.

Please adhere to the reference guidelines outlined above.

D. Opinion Papers, Controversies

The structure of these papers will vary from an original paper according to the nature of the topic and argument. Opinion papers present the authors' comprehensive views on current developments in the area and discuss perspectives for the future. Controversies describe a relevant ongoing scientific dispute from an unbiased point of view. They should not exceed 10 type-written pages, with a maximum of 40 references.

Please adhere to the guidelines concerning references outlined above.

E. Short Communications

Short Communications are completed projects of smaller scope and should contain new clinical and experimental data of immediate interest.

1. They should not exceed 2 printed pages (i.e. 6 type-written double-spaced pages in manuscript 30 lines of 60 letters each) and may include 1 table and 1 figure. The list of references at the end of the paper should not exceed 10 citations.
2. The guidelines for the structure of Short Communications are the same as for Original Articles with the following exceptions:
 - a) no keywords and b) no titles of the papers in the list of references.

F. Letters

This section has been introduced to encourage authors to engage in a free exchange of ideas. The opinions presented do not necessarily reflect the opinions of the Editors.

Page Charges

The publisher will impose a page charge of 160 € per printed page (including 19% VAT) starting with the seventh page.

Reproduction of Color Figures

The journal's fee for color reproduction amounts to € 440 for the first color figure and € 80 for any further figure (including 19% VAT).

Proofs and Reprints as PDF File

Galley proofs will be sent to the corresponding author as a PDF file. At this stage of the production process, only minor corrections (typos, obvious errors in the production process) are accepted. **All other alterations will trigger a de-novo submission.**

The corresponding author receives a PDF file of the published article free of charge.

Copyright

The publisher holds the copyright to all material appearing in the journal. A Copyright Transfer Agreement will be sent to the corresponding author together with the galley proofs. The agreement must be completed and returned to the publishers before the article can be published. **If material taken from foreign sources (including figures, etc.) is included in a manuscript submitted to the Journal it must be indicated as such by citation of the original source and, whenever necessary, permission for reproduction must be obtained from the respective publishing company.**

Editor-in-Chief:

Martin Wehling, MD
Professor of Medicine
Institute of Experimental and
Clinical Pharmacology and Toxicology
Medical Faculty Mannheim
University of Heidelberg
Maybachstr. 14
68169 Mannheim
Germany
E-mail: arzneimittelforschung@thieme.de

Letter of permission to use article:

Von: Melinda Barkhuizen [mailto:21686866@nwu.ac.za]

Gesendet: Monday, November 25, 2013 2:24 PM

An: Wenzel, Dr. Regina

Betreff: Permission to use article for scholarly purposes

GEORG THIEME VERLAG

Scientific Publications Division

Dear Dr. Wentzel

Article 1: Barkhuizen, M., Petzer, A., Petzer, J.P. The inhibition of monoamine oxidase by phenformin and pentamidine. Arzneimittelforschung/Drug research. Accepted. Art. 2013-10-0434.

With this letter, I ask permission to use the above manuscript for scholarly purposes, specifically to incorporate unedited (by Georg Thieme Verlag) versions of the article into the dissertation for my Masters degree. Hard copies of my dissertation will be kept in the libraries of the North-West University. In addition my study leader and the examiners of the dissertations will each obtain a copy of the dissertations.

Thank you,

Melinda Barkhuizen

Dept. of Pharmaceutical Chemistry

North-West University

Private bag X6001

Potchefstroom, 2520, South Africa

Tel. 018-299 2206

Fax 018 299 4243

Dear Ms Barkhuizen,

We herewith grant you permission to use the final manuscript version of the article mentioned below for incorporation into your Master's thesis. Please note that the permission covers only this use, should you wish to use the article for further/other purposes, please contact me again.

Thank you and very best regards,

Regina Wenzel

Dr. Regina Wenzel

Programmplanung / Publishing Editor

Georg Thieme Verlag KG

Rüdigerstraße 14 | 70469 Stuttgart

Fon +49 711/8931-102

Fax +49 711/8931-392

regina.wenzel@thieme.de

www.thieme.de

Georg Thieme Verlag KG | Rüdigerstr. 14 | 70469 Stuttgart

Rechtsform: KG | Sitz und Handelsregister: Stuttgart, HRA 3499

Annexure C – Contributions of authors

Author	Contributions	Consent*
M. Barkhuizen	Responsible for planning the study and carrying out the modelling and enzymology. Writing of the dissertation and articles.	
Prof. J.P. Petzer	Design of the project.	
Dr. A. Petzer	Assistance with the enzymology.	

*I declare that I have approved the article and that my role in the study was as indicated above. I hereby give my consent that the article may be published as part of the dissertation of M. Barkhuizen.